Compare General Dynamics Corporation (GD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Repligen Corporation Common Stock — how do they compare? General Dynamics Corporation trades at $337.24 (market cap $89.94B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: General Dynamics Corporation is far larger — about 8.1× Repligen Corporation Common Stock's market cap, and General Dynamics Corporation pays a 1.91% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 86 Days and Repligen Corporation Common Stock for 0 Days on average.
| GD | RGEN | |
|---|---|---|
Market Cap | $89.94B | $11.14B |
Volume | 1,284,020 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $395.97 | $194.57 |
52-Week Low | $312.53 | $102.87 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $95.08B | $11.02B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $334.66, down 0.24% with bearish technical signals despite strong fundamentals. The defense contractor shows robust revenue growth, increasing from $47.7B in 2024 to $52.5B in 2025, with consistent earnings beats. Analyst consensus remains bullish with a $414.57 price target, supported by strong Pentagon spending and dividend stability.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.27) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend champion status provide downside protection. Upside potential exists if technical resistance at $337 is breached.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
